Literature DB >> 1310133

Monokines inhibiting erythropoietin production in human hepatoma cultures and in isolated perfused rat kidneys.

W Jelkmann1, H Pagel, M Wolff, J Fandrey.   

Abstract

The blood level of erythropoietin (Epo) is often anomalously low in anemic patients with inflammatory or malignant diseases. Therefore, we studied effects of pure recombinant immunomodulatory peptides on Epo formation in cultures of the human hepatoma cell line, HepG2. Interleukin (IL)-1 beta, IL-1 alpha, and tumor necrosis factor alpha lowered Epo production with half-maximal inhibition at 2, 5, and 20 U/ml, respectively. IL-6, transforming growth factor beta 2 and interferon gamma did not inhibit. Furthermore, IL-1 beta (10 U/ml) proved to block Epo formation in isolated serum-free perfused rat kidneys. Proposedly, monokines play a role in the pathogenesis of Epo deficiency in various diseases.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1310133     DOI: 10.1016/0024-3205(92)90338-p

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  33 in total

1.  Recombinant erythropoietin therapy in renal and nonrenal anemia.

Authors:  A J Erslev
Journal:  West J Med       Date:  1992-08

Review 2.  Statins, inflammation and kidney disease.

Authors:  Vera Krane; Christoph Wanner
Journal:  Nat Rev Nephrol       Date:  2011-05-31       Impact factor: 28.314

3.  Interleukin 1 beta and phorbol ester induce tumour necrosis factor alpha production in a hepatic cell line (HepG2).

Authors:  S Frede; J Fandrey; W Jelkmann
Journal:  Pflugers Arch       Date:  1996-04       Impact factor: 3.657

4.  Persistent inflammation and anemia among critically ill septic patients.

Authors:  Tyler J Loftus; Juan C Mira; Julie A Stortz; Tezcan Ozrazgat-Baslanti; Gabriella L Ghita; Zhongkai Wang; Babette A Brumback; Ricardo F Ungaro; Azra Bihorac; Christiaan Leeuwenburgh; Frederick A Moore; Lyle L Moldawer; Scott C Brakenridge; Philip A Efron; Alicia M Mohr
Journal:  J Trauma Acute Care Surg       Date:  2019-02       Impact factor: 3.313

5.  Relationship between renal anemia and prognostic stages of IgA nephropathy.

Authors:  Seiki Aruga; Tomohide Horiuchi; Ichiyu Shou; Kyouichi Tashiro; Atsushi Kurusu; Mitsumine Fukui; Satoshi Horikoshi; Yasuhiko Tomino
Journal:  J Clin Lab Anal       Date:  2005       Impact factor: 2.352

Review 6.  Anaemia in systemic lupus erythematosus: from pathophysiology to clinical assessment.

Authors:  S Giannouli; M Voulgarelis; P D Ziakas; A G Tzioufas
Journal:  Ann Rheum Dis       Date:  2005-08-03       Impact factor: 19.103

7.  Endogenous erythropoietin as part of the cytokine network in the pathogenesis of experimental autoimmune encephalomyelitis.

Authors:  Manuela Mengozzi; Ilaria Cervellini; Paolo Bigini; Sara Martone; Antonella Biondi; Rosetta Pedotti; Barbara Gallo; Sara Barbera; Tiziana Mennini; Mariaserena Boraso; Marina Marinovich; Edwige Petit; Myriam Bernaudin; Roberto Bianchi; Barbara Viviani; Pietro Ghezzi
Journal:  Mol Med       Date:  2008-07-30       Impact factor: 6.354

8.  Immunocytochemical demonstration of erythropoietin in hypoxic human hepatoma cultures.

Authors:  C Herkens; M Wolff; J Fandrey; F Schuler; W Jelkmann
Journal:  Histochemistry       Date:  1993-10

9.  Perioperative plasma erythropoietin levels in hip arthroplasty.

Authors:  A Lorentz; K U Eckardt; P M Osswald; C Kruse
Journal:  Ann Hematol       Date:  1994-03       Impact factor: 3.673

10.  Inflammation and its impact on anaemia in chronic kidney disease: from haemoglobin variability to hyporesponsiveness.

Authors:  Angel L M de Francisco; Peter Stenvinkel; Sophie Vaulont
Journal:  NDT Plus       Date:  2009-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.